Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.8
(-0.48%)
CNY 20.8
(-0.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 385.6 Million | 166.4 Million | 201.57 Million | 214.48 Million | 179.9 Million | 109.76 Million |
| Net Income | 289.06 Million | 208.21 Million | 168.28 Million | 157.22 Million | 186.13 Million | 136.82 Million |
| Depreciation & Amortization | 79.11 Million | 69.24 Million | 54.77 Million | 32.02 Million | 27.89 Million | 23.13 Million |
| Deferred income taxes | -3.57 Million | -3.77 Million | -2.57 Million | 3.65 Million | -3.04 Million | - |
| Stock-based compensation | 8.15 Million | 6.34 Million | - | - | - | - |
| Change in working capital | 274.69 Thousand | -144.03 Million | -24.87 Million | 15.4 Million | -8.26 Million | -56.38 Million |
| Other non-cash items | 515.87 Thousand | 30.41 Million | 3.39 Million | 9.82 Million | -25.85 Million | 6.18 Million |
| Investing Cash Flow | -365.27 Million | -256.78 Million | -262.34 Million | -157 Million | -82.1 Million | -75.95 Million |
| Investments in PPE | -305.47 Million | -216.22 Million | -250.61 Million | -158.79 Million | -72.47 Million | -94.14 Million |
| Acquisitions | 61.09 Million | 625.13 Thousand | 597.34 Thousand | 159.62 Million | -12.24 Million | - |
| Investment purchases | -1.43 Million | -91.44 Million | -111.13 Million | -52 Million | -200 Million | -209.7 Million |
| Sales/Maturities of investments | 27.49 Thousand | 50.25 Million | 96.81 Million | 52.96 Million | 201.44 Million | 211.23 Million |
| Other Investing Activities | -120 Million | 0.99 | 2 Million | -158.79 Million | 1.17 Million | 16.64 Million |
| Financing Cash Flow | 49.01 Million | -14.91 Million | -52.48 Million | 246.94 Million | 759.79 Thousand | -57.03 Million |
| Debt repayment | -69.47 Million | -998.29 Thousand | -4.36 Million | - | - | -21 Million |
| Dividends payments | -64.99 Million | -52.13 Million | -48.12 Million | -36 Million | - | -36.03 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | -29.34 Million | -998.2 Thousand | - |
| Other Financing Activities | 46.54 Million | 38.42 Million | -0.02 | 282.94 Million | 759.79 Thousand | -36.03 Million |
| Accounts receivables | -98.17 Million | -84.83 Million | 11.29 Million | -20.72 Million | -21.19 Million | - |
| Accounts payables | 174.54 Million | 70.55 Million | 55.4 Million | 30.64 Million | 27.44 Million | - |
| Inventory | -72.51 Million | -125.97 Million | -89 Million | 1.82 Million | -11.46 Million | -38.48 Million |
| Other working capital | 34.27 Million | -3.77 Million | -2.57 Million | 3.65 Million | -3.04 Million | -17.89 Million |
| Cash at beginning of period | 338.54 Million | 440.33 Million | 557.41 Million | 259.29 Million | 167.07 Million | 195.34 Million |
| Cash at end of period | 414.01 Million | 338.54 Million | 440.33 Million | 557.41 Million | 259.29 Million | 167.07 Million |
| Capital Expenditure | -305.47 Million | -216.22 Million | -250.61 Million | -158.79 Million | -72.47 Million | -94.14 Million |
| Effect of forex changes on cash | 6.11 Million | 3.5 Million | -3.82 Million | -6.29 Million | -6.34 Million | -5.04 Million |
| Net cash flow / Change in cash | 75.46 Million | -101.79 Million | -117.08 Million | 298.12 Million | 92.21 Million | -28.27 Million |
| Free Cash Flow | 80.13 Million | -49.81 Million | -49.04 Million | 55.68 Million | 107.42 Million | 15.62 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 95.2 Million | 106.4 Million | 82.18 Million | 289.06 Million | 56.87 Million | 136.64 Million |
| Depreciation & Amortization | - | 22.21 Million | 22.21 Million | 79.11 Million | 20.97 Million | -38.18 Million |
| Deferred income taxes | - | - | - | -3.57 Million | - | -10.15 Million |
| Stock-based compensation | - | 10.71 Million | - | 8.15 Million | 8.15 Million | -17.69 Million |
| Change in working capital | - | -96.17 Million | - | 274.69 Thousand | -136.42 Million | 52.78 Million |
| Other non-cash items | 39.73 Million | -5.17 Million | 7.71 Million | 515.87 Thousand | 46.77 Million | 17.91 Million |
| Investing Cash Flow | -459.88 Million | 5.91 Million | -140.01 Million | -365.27 Million | -231.76 Million | -26.13 Million |
| Investments in PPE | -184.45 Million | -113.2 Million | -140.55 Million | -305.47 Million | -111.42 Million | -85.69 Million |
| Acquisitions | -200.48 Million | 123.61 Thousand | 63 Thousand | 61.09 Million | 62.47 Million | 187.98 Thousand |
| Investment purchases | 585.33 Million | -758.13 Million | - | -1.43 Million | -121.43 Million | -187.98 Thousand |
| Sales/Maturities of investments | -647.56 Million | 757.13 Million | 476.84 Thousand | 27.49 Thousand | -59.03 Million | 58.23 Million |
| Other Investing Activities | -213.19 Million | 120 Million | 539.85 Thousand | -120 Million | -121.13 Million | 1.31 Million |
| Financing Cash Flow | 745.15 Million | -41.17 Million | 32.32 Million | 49.01 Million | 46.01 Million | 30.76 Million |
| Debt repayment | -656.06 Million | -51.85 Million | -34.97 Million | -69.47 Million | -27.92 Million | -249.13 Thousand |
| Dividends payments | -3.42 Million | -89.36 Million | -246.52 Thousand | -64.99 Million | -64.99 Million | -344.37 Thousand |
| Common Stock Repurchased | - | - | - | - | -1.2 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 85.66 Million | 8260.72 | -2.4 Million | 46.54 Million | 18.46 Million | 31.35 Million |
| Accounts receivables | - | -65.51 Million | - | -98.17 Million | -98.17 Million | -728.34 Thousand |
| Accounts payables | - | - | - | 174.54 Million | - | 20.78 Million |
| Inventory | - | -43.63 Million | - | -72.51 Million | -72.51 Million | 53.51 Million |
| Other working capital | - | 12.97 Million | - | 34.27 Million | 34.27 Million | -20.78 Million |
| Cash at beginning of period | 433.98 Million | 533.57 Million | 414.41 Million | 338.54 Million | 504.57 Million | 359.65 Million |
| Cash at end of period | 856.97 Million | 446.91 Million | 400.66 Million | 414.01 Million | 414.01 Million | 504.57 Million |
| Capital Expenditure | -184.45 Million | -113.2 Million | -140.55 Million | -305.47 Million | -111.42 Million | -85.69 Million |
| Effect of forex changes on cash | 3.55 Million | -10.03 Million | 4.52 Million | 6.11 Million | -1.52 Million | -1.02 Million |
| Net cash flow / Change in cash | 422.98 Million | -86.65 Million | -13.74 Million | 75.46 Million | -90.56 Million | 144.92 Million |
| Free Cash Flow | -49.51 Million | -34.18 Million | -50.65 Million | 80.13 Million | -28.75 Million | 55.63 Million |
7501
RARE
2941
DIB
7746
MILDEF